LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.Learn More
We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.See All
There are over 290 million people in China with cardiovascular disease and more than 100 million with chronic kidney disease. Cardiorenal disease is the leading cause of death in China today.
5.5 people die from cancer every minute in China alone and every year there are more than 4.5 million new cases diagnosed.
October 20, 2021
LianBio Annouces Launch of Initial Public Offering
October 13, 2021
LianBio Appoints Jesse Wu to Board of Directors
October 12, 2021
LianBio Appoints Susan Silbermann to Board of Directors
October 3, 2021
LianBio Appoints Michael Humphries as Chief Scientific Advisor